ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2024
Novel avenues of tau research.
Abstract readReview
In one paragraph
Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions.Molecular cancer · 2025Review
- Tauopathies: Calmodulin Regulates Tau Hyperphosphorylation and Its Transformation into Disease-Specific Aggregates.Biomolecules · 2025Review
- Review
- Return of research results across the Alzheimer's Disease Research Centers network.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- The Genetic Background of the Immunological and Inflammatory Aspects of Progressive Supranuclear Palsy.International journal of molecular sciences · 2025Review
- Chemical Synthesis Reveals Pathogenic Role ofJournal of the American Chemical Society · 2025Article
- Precision Medicine in Neurodegenerative Diseases: Genomic Approaches to Target Amyloid-β, Tau, and Alpha-Synuclein Pathways.Current genomics · 2025Review
- Symposium: What Does the Microbiome Tell Us about Prevention and Treatment of AD/ADRD?The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024Review
- Altered Protein Palmitoylation as Disease Mechanism in Neurodegenerative Disorders.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024Review
- Pathogenic tau induces an adaptive elevation in mRNA translation rate at early stages of disease.Aging cell · 2024Article
- Integrating amyloid and tau imaging with proteomics and genomics in Alzheimer's disease.Cell reports. Medicine · 2024Review
- Novel avenues of tau research.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Claire E SextonAlzheimer's Association, Chicago, Illinois, USA.ORCID 0000-0002-3846-2986
Gal BitanDepartment of Neurology, David Geffen School of Medicine, Brain Research Institute, Molecular Biology Institute, University of California Los Angeles (UCLA), Los Angeles, California, USA.
Kathryn R BowlesUK Dementia Research Institute at the University of Edinburgh, Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK.
Miroslaw BrysEli Lilly & Co., Indianapolis, Indiana, USA.
Luc BuéeUniv Lille, Inserm, CHU-Lille, Lille Neuroscience and Cognition, LabEx DISTALZ, Place de Verdun, Lille, France.
Mahmoud Bukar MainaSussex Neuroscience, School of Life Sciences, University of Sussex, Falmer, UK.
Claire D ClellandMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, California, USA.
Ann D CohenUniversity of Pittsburgh, School of Medicine, Department of Psychiatry and Alzheimer's disease Research Center, Pittsburgh, Pennsylvania, USA.
John F CraryDepartments of Pathology, Neuroscience, and Artificial Intelligence & Human Health, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Jeffrey L DageDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Kristophe DiazCurePSP, Inc, New York, New York, USA.
Bess FrostSam & Ann Barshop Institute for Longevity & Aging Studies Glenn Biggs Institute for Alzheimer's & Neurodegenerative Disorders Department of Cell Systems and Anatomy University of Texas Health San Antonio, San Antonio, Texas, USA.
Li GanHelen and Robert Appel Alzheimer Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, New York, USA.
Alison M GoateDepartment of Genetics & Genomic Sciences, Ronald M. Loeb Center for Alzheimer's disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Lawrence I GolbeCurePSP, Inc, New York, New York, USA.
Oskar HanssonClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Celeste M KarchDepartment of Psychiatry, Washington University in St. Louis, St. Louis, Missouri, USA.
Hartmuth C KolbJanssen R&D, Neuroscience, San Diego, California, USA.
Renaud La JoieMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, California, USA.
Suzee E LeeMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, California, USA.
Diana MatallanaAging Institute, Neuroscience Program, Psychiatry Department, School of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia.
Bruce L MillerMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, California, USA.
Chiadi U OnyikeDivision of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University School of Medicine, Baltimore, Baltimore, Maryland, USA.
Yakeel T QuirozDepartments of Psychiatry and Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Jessica E RexachProgram in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Jonathan D RohrerDepartment of Neurodegenerative Disease, Dementia Research Centre, University College London Institute of Neurology, Queen Square, London, UK.
Amy RommelRainwater Charitable Foundation, Fort Worth, Texas, USA.
Ghazaleh Sadri-VakiliSean M. Healey &AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts, USA.
Suzanne E SchindlerDepartment of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
Julie A SchneiderRush Alzheimer's Disease Center, Chicago, Illinois, USA.
Reisa A SperlingCenter for Alzheimer Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Charlotte E TeunissenNeurochemistry Laboratory, Clinical Chemistry department, Amsterdam Neuroscience, Program Neurodegeneration, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Stacie C WeningerFBRI, Cambridge, Massachusetts, USA.
Susan L WorleyIndependent Science Writer, Bryn Mawr, Pennsylvania, USA.
Hui ZhengHuffington Center on Aging, Baylor College of Medicine, Houston, Texas, USA.
Maria C CarrilloAlzheimer's Association, Chicago, Illinois, USA.
Funding
Project 3: Biomarkers for DS Clinical TrialsU19AG068054 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TUDORASCU, DANA L · 2020 to 2025
$103.7MResearch Education ComponentP30AG066468 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Julia K Kofler · 2020 to 2026
$29.4MRush Alzheimer's Disease Research CenterP30AG072975 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI Lisa L Barnes, Julie A. Schneider · 2021 to 2026
$24.7MUS-South American Initiative for Genetic-Neural-Behavioral Interactions in Human Neurodegenerative ResearchR01AG057234 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Claudia Duran-Aniotz, Agustin M. Ibanez · 2019 to 2026
$6.1McGAS inhibitors for Alzheimer's disease treatmentR01AG074541 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI GAN, LI, SINHA, SUBHASH C · 2021 to 2025
$4.2MMaladaptive antiviral pathways in Alzheimer's diseaseR01AG072758 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI GAN, LI · 2021 to 2025
$4.1MGenome-wide identification and characterization of Alzheimer's Disease-associated enhancersR01AG077899 · NIA · CORNELL UNIVERSITY · PI Li Gan, JOHN T LIS · 2022 to 2026
$4.0MMechanisms of tau- and aging-induced neurological dysfunction: Focus on the nucleusR01AG057896 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI FROST, BESS · 2019 to 2023
$2.8MBiomarkers for parkinsonian disorders in CNS-originating extracellular vesiclesRF1NS126406 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BITAN, GAL · 2023 to 2024
$2.6MInvestigation of the Effect of Structural Modifications of Tau on Assembly State and SeedingRF1AG054000 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BITAN, GAL · 2017 to 2021
$2.1MCRISPR-Cas9 editing in C9orf72 patient derived iPSCK08NS112330 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CLELLAND, CLAIRE · 2020 to 2024
$1.2MSingle cell and tissue level functional genomic analysis of astrocyte-related mechanisms in tauopathyK08NS105916 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REXACH, JESSICA E · 2019 to 2023
$1.1MAlzheimer's Association SG-20-725707-ReDLatFIC NIH HHS R01AG057234Medical Research Council MR/T046015/1NIA NIH HHS P30 AG072975NIA NIH HHS R01 AG057234NIA NIH HHS R01 AG057896NIA NIH HHS R01 AG072758NIA NIH HHS R01 AG074541NIA NIH HHS R01 AG077899NIA NIH HHS RF1 AG054000NIA NIH HHS U19 AG068054NINDS NIH HHS K08 NS105916NINDS NIH HHS K08 NS112330NINDS NIH HHS R21 NS130326NINDS NIH HHS RF1 NS126406
Abstract
introductionThe pace of innovation has accelerated in virtually every area of tau research in just the past few years.
methodsIn February 2022, leading international tau experts convened to share selected highlights of this work during Tau 2022, the second international tau conference co-organized and co-sponsored by the Alzheimer's Association, CurePSP, and the Rainwater Charitable Foundation.
resultsRepresenting academia, industry, and the philanthropic sector, presenters joined more than 1700 registered attendees from 59 countries, spanning six continents, to share recent advances and exciting new directions in tau research. DISCUSSION: The virtual meeting provided an opportunity to foster cross-sector collaboration and partnerships as well as a forum for updating colleagues on research-advancing tools and programs that are steadily moving the field forward.
Indexed as
Alzheimer DiseaseTauopathiesHumanstau Proteinstau Proteinsbiomarkerstautauopathiestau-PETtherapeutics
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.